Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Matthew Wilson, MD BSc, MRCP, Catherine Ogilvie, MD, Jennifer Travers, MD, Michelle Martin, Jonathan Allan, Pam McKay, MD, Mike Leach, MD

Blood (2019) 134 (Supplement_1): 5285.

https://doi.org/10.1182/blood-2019-126704

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Blood (2018) 132 (Supplement 1): 705.

https://doi.org/10.1182/blood-2018-99-117671

Published: 2018

Journal Articles

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics

Eric Robert Fedyk, PhD, Deborah Berg, RN, MSN, Glenda Smithson, PhD, Jose Estevam, Lachy Mclean, MD PhD, Kristina Allikmets, MD PhD, Antonio Palumbo, MD

Blood (2018) 132 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2018-99-112916

Published: 2018

Journal Articles

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda L. Neuman, MD MBA, Renee Ward, MD PhD, David Arnold, Daniel L. Combs, BS, Deena Gruver, MS, Wendy Hill, MBA, Josué Mfopou Kunjom, MD PhD, Langdon L. Miller, MD, Judith A. Fox, PhD

Blood (2016) 128 (22): 2032.

https://doi.org/10.1182/blood.V128.22.2032.2032

Published: 2016

Journal Articles

A Study of Adherence to Restrictive RBC Transfusion and 30 Day Patient Outcomes

Zhen Wang, MD, Elaine Zhai, DO, Aleksic Sandra, MD, Kibola Adam, MD, Richard May, MD, Teja Ganta, MD, Mirela Feurdean, MD, Neil Kothari, MD, Victor Chang, MD

Blood (2016) 128 (22): 5037.

https://doi.org/10.1182/blood.V128.22.5037.5037

Published: 2016

Journal Articles

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Monique Minnema, Kazem Nasserinejad, MA, Bouke Hazenberg, MD PhD, Ute Hegenbart, Lucien Noens, MD PhD, Paula F. Ypma, MD, Sonja Zweegman, MD PhD, Lidwine Winnifred Tick, MD PhD, Annemiek Broijl, MD PhD, Harry R. Koene, MD PhD, Gerard M.J. Bos, MD PhD, Pieter Sonneveld, MD PhD, Stefan O. Schoenland, MD

Blood (2016) 128 (22): 4628.

https://doi.org/10.1182/blood.V128.22.4628.4628

Published: 2016

Journal Articles

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

John H. Chen, Daniel J. Lenihan, MD, Sharon E. Phillips, MSPH, Madan H. Jagasia, Stacey A. Goodman, MD MS, Adetola A. Kassim, MD MS, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, MD, Tarsheen K. Sethi, MD MS, David A. Slosky, Oluchi C. Ukaegbu, MD, Robert F. Cornell

Blood (2015) 126 (23): 5363.

https://doi.org/10.1182/blood.V126.23.5363.5363

Published: 2015

Journal Articles

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Dan T. Vogl, Noopur Raje, MD, Parameswaran Hari, MBBS, MD MRCP, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, PhD MD, Paul G. Richardson, Sagar Lonial, MD, David Tamang, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 4764.

https://doi.org/10.1182/blood.V124.21.4764.4764

Published: 2014

Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 294.

https://doi.org/10.1182/blood.V124.21.294.294

Published: 2014

Journal Articles

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Ran Reshef, MD, James K. Mangan, MDPhD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, Edward A. Stadtmauer, MD, Robin E. Blauser, BSN RN, Lee P. Richman, BA, Austin P. Huffman, BA, Alex Ganetsky, PharmD, Edward P. Acosta, PharmD, James A. Hoxie, MD, Rosemarie Mick, MS, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 2491.

https://doi.org/10.1182/blood.V124.21.2491.2491

Published: 2014

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

Daniel J. DeAngelo, MD, Ph.D, Harry P Erba, MD, Michael B Maris, MD, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Faiz Anwer, MD, Jessica K Altman, MD, Zhaowei Hua, Ph.D, Stephen J Blakemore, Ph.D, Hélène Faessel, Ph.D, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2013) 122 (21): 1443.

https://doi.org/10.1182/blood.V122.21.1443.1443

Published: 2013

Journal Articles

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 4389.

https://doi.org/10.1182/blood.V122.21.4389.4389

Published: 2013

Journal Articles

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Laurie H. Sehn, MD, MPH, Andre Goy, MD, Fritz C. Offner, MD, PhD, Giovanni Martinelli, MD, Jonathan Friedberg, MD, Susan F. Lasserre, MSc, Gregg Fine, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 269.

https://doi.org/10.1182/blood.V118.21.269.269

Published: 2011

Journal Articles

Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma

Brian G. Till, MD, Michael C. Jensen, MD, Xiaojun Qian, Jinjuan Wang, Ajay K Gopal, MD, David G. Maloney, Catherine G. Lindgren, Yukang Lin, John M. Pagel, MD, PhD, Lihua E Budde, MD., PhD, Andrew Raubitschek, MD, Stephen Forman, Philip Greenberg, Stanley R. Riddell, MD, Oliver W. Press, MD, PhD

Blood (2010) 116 (21): 561.

https://doi.org/10.1182/blood.V116.21.561.561

Published: 2010

Journal Articles

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Robert A. Baiocchi, Lapo Alinari, Thomas S. Lin, Pierluigi Porcu, Jeffrey Jones, Joseph Flynn, William Hicks, Margaret S. Lucas, Lai Wei, Jeffrey S. Johnston, John C. Byrd

Blood (2008) 112 (11): 3053.

https://doi.org/10.1182/blood.V112.11.3053.3053

Published: 2008

Journal Articles

A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

Edward A. Stadtmauer, MD, David Siegel, MD, PhD, Dan T Vogl, MD, MS, James Stinnett, MD, Geetha Narayanan, MD, P.P. Bapsy, MD, Trivadi Ganesan, MBBS, MD, MNAMS, FRCP, MA, PhD, Minish Jain, MD, Sripada V.S.S Prasad, MD, DMs, Douglas S McNair, MD, PhD, Linda DeYoung, PhD, Alice Lane, Bruce Silver, MD

Blood (2008) 112 (11): 5188.

https://doi.org/10.1182/blood.V112.11.5188.5188

Published: 2008

Journal Articles

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Steven Grant, MD, Daniel Sullivan, David Roodman, MD, PhD, Robert K Stuart, MD, Edward Perkins, Sarah Kolla, Viswanathan Ramakrishnan, John Wright, MD, PhD, Alexander Dimitri Colevas, M B Tombes, John D Roberts

Blood (2008) 112 (11): 1573.

https://doi.org/10.1182/blood.V112.11.1573.1573

Published: 2008

NARROW

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

A Study of Adherence to Restrictive RBC Transfusion and 30 Day Patient Outcomes

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study

Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only